<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01126879</url>
  </required_header>
  <id_info>
    <org_study_id>NCI 09U2</org_study_id>
    <secondary_id>NCI-2010-00941</secondary_id>
    <secondary_id>STU00019487</secondary_id>
    <secondary_id>P50CA090386</secondary_id>
    <nct_id>NCT01126879</nct_id>
  </id_info>
  <brief_title>Genistein in Treating Patients With Prostate Cancer</brief_title>
  <official_title>Phase 2 Trial of Genistein in Men With Circulating Prostate Cancer Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Genistein may stop the growth of tumor cells by blocking some of the enzymes
      needed for cell growth.

      PURPOSE: This randomized phase II trial is studying how well genistein works in treating
      patients with prostate cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Determine whether genistein treatment will decrease the number of circulating prostate
      cells (CPCs) in the peripheral blood as measured by qRT-PCR for PSA performed on RNA
      extracted from peripheral blood mononuclear cells (PBMNCs).

      SECONDARY OBJECTIVES:

      I. Determine the natural history of circulating prostate cells (CPCs) in a cohort of subjects
      prior to and post radical prostatectomy.

      II. Compare the measurement of PSA between three separate methods: in CPCs by qRT-PCR, in
      serum by the standard clinical chemistry assay (i.e., ELISA), and in plasma and serum by the
      nano-PSA assay.

      III. Measure the effect of genistein on gene and protein expression in prostate tissue by
      qRT-PCR and immunohistochemistry, respectively, for the following genes and their respective
      protein products: HSP27, MMP-2, ALK-2, BASP1, and HCF2.

      OUTLINE:

      Patients are randomized to 1 of 2 treatment arms.

      ARM I: Patients receive oral genistein once daily for 3 months beginning at least 1 month
      prior to radical prostatectomy.

      ARM II: Patients receive oral placebo once daily for 3 months beginning at least 1 month
      prior to radical prostatectomy.

      All patients undergo radical prostatectomy at least 2 weeks, but not more than 3 months
      following the start of therapy.

      After completion of study treatment, patients are followed at 1, 6, and 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Closed due to low accrual
  </why_stopped>
  <start_date type="Actual">February 3, 2011</start_date>
  <completion_date type="Actual">December 28, 2013</completion_date>
  <primary_completion_date type="Actual">May 9, 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Circulating Prostate Cells (CPCs) in the Blood as Determined by qRT-PCR for PSA on RNA Extracted From PBMNCs</measure>
    <time_frame>At screening, after 1-month of treatment, at surgery and at 1 and 12 months after surgery</time_frame>
    <description>Blood will be collected to analyze the number of CPC's at screening, after 1-month of treatment, at surgery and at 1 and 12 months after surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Natural History of Circulating Prostate Cells (CPCs) in a Cohort of Subjects Prior to and Post Radical Prostatectomy</measure>
    <time_frame>At baseline, 1 and 12 months after surgery</time_frame>
    <description>Blood will be drawn to analyze the natural history of circulating prostate cells (CPCs) in a cohort of subjects at baseline and 1 and 12 months after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure the Effect of Genistein on Select Gene and Protein Expressions in Prostate Tissue</measure>
    <time_frame>At baseline and at time of surgery</time_frame>
    <description>At baseline and time of surgery, tissue will be collected to measure the effect of genistein on select gene and protein expressions in prostate tissue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of PSA in Serum and Plasma by Nanotechnology</measure>
    <time_frame>At screening, after 1-month of treatment, at surgery and at 1 and 12 months after surgery</time_frame>
    <description>Blood will be collected to measure PSA in serum and plasma by nanotechnology at screening, after 1-month of treatment, at surgery and at 1 and 12 months after surgery.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Adenocarcinoma of the Prostate</condition>
  <condition>Recurrent Prostate Cancer</condition>
  <condition>Stage I Prostate Cancer</condition>
  <condition>Stage II Prostate Cancer</condition>
  <condition>Stage III Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral genistein once daily for 3 months beginning at least 1 month prior to radical prostatectomy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive an oral placebo once daily for 3 months beginning at least 1 month prior to radical prostatectomy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>genistein</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>CI 75610</other_name>
    <other_name>Genestein</other_name>
    <other_name>genisteol</other_name>
    <other_name>genisterin</other_name>
    <other_name>prunetol</other_name>
    <other_name>sophoricol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>PLCB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic conventional surgery</intervention_name>
    <description>Radical prostatectomy for treatment of prostate cancer</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion

          -  Participants must have a pathologic diagnosis of prostate cancer within the past 6
             months, have clinical stage T1-3 disease, PSA &gt;= 10, Gleason score &gt;= 8, and have
             elected to undergo radical prostatectomy; those found to have detectable circulating
             prostate cancer cells in the blood as detected by qRT-PCR for PSA will be eligible to
             proceed onto the treatment phase of the protocol; pathology slides used for diagnosis
             will be submitted to the SPORE tissue pathology core for review

          -  ECOG performance status 0-1

          -  Hemoglobin &gt; 9.0gm/dl

          -  Platelets &gt;= 100 K/uL

          -  ANC &gt; 1000/uL

          -  AST (SGOT)/ALT (SGPT) &lt; 3X upper limit of normal

          -  Creatinine &lt; 2.0 mg/dl

          -  Total bilirubin &lt; 2 mg/dl (Note: Subjects with a higher level of bilirubin due to a
             familial defect in bilirubin metabolism will be considered on an individual basis)

          -  Participants must agree not to take soy supplements

          -  Ability to understand and the willingness to sign a written informed consent document

          -  Willingness to take study agent for at least 2 weeks prior to radical prostatectomy

        Exclusion

          -  History of venous thrombosis within past year

          -  Participants must not be receiving active therapy for neoplastic disorders (including
             hormone or radiation therapy for prostate cancer)

          -  Participants may not be receiving any other investigational agents

          -  Known soy intolerance

          -  Medical conditions that, in the opinion of the investigators, would jeopardize either
             the patient or the integrity of the data obtained
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Catalona</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>May 18, 2010</study_first_submitted>
  <study_first_submitted_qc>May 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2010</study_first_posted>
  <results_first_submitted>May 1, 2019</results_first_submitted>
  <results_first_submitted_qc>June 24, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 2, 2019</results_first_posted>
  <last_update_submitted>August 27, 2019</last_update_submitted>
  <last_update_submitted_qc>August 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Genistein</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study opened on October 21, 2010 with an accrual goal of 30 patients with firs the patient enrolled March 3, 2011. The study was designed as a randomized blinded drug/placebo study but was amended to a single arm drug study and accrual reduced to 18. Study closed permanently on May 28, 2014 due to low accrual with 12 patients treated on study.</recruitment_details>
      <pre_assignment_details>Patients entered the study and were treated in a double blinded fashion with a ration of 2:1 Genistein:Placebo. Unblinding occured if it was medically necessary otherwise blinding was maintained until the time of data review.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm I - Genistein</title>
          <description>Patients receive oral genistein once daily for 3 months beginning at least 1 month prior to radical prostatectomy.
Genistein: Given orally
Therapeutic conventional surgery: Radical prostatectomy for treatment of prostate cancer</description>
        </group>
        <group group_id="P2">
          <title>Arm II - Placebo</title>
          <description>Patients receive an oral placebo once daily for 3 months beginning at least 1 month prior to radical prostatectomy.
Placebo: Given orally
Therapeutic conventional surgery: Radical prostatectomy for treatment of prostate cancer</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Started 3 Months of Genistein/Placebo</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Prostatectomy or Radiation</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed 3 Months Genistein/Placebo</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Progressive Disease</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm I - Genistein</title>
          <description>Patients receive oral genistein or placebo once daily for 3 months beginning at least 2 weeks prior to radical prostatectomy.
Genistein: Given orally
Therapeutic conventional surgery: Radical prostatectomy for treatment of prostate cancer</description>
        </group>
        <group group_id="B2">
          <title>Arm II - Placebo</title>
          <description>Patients receive oral genistein or placebo once daily for 3 months beginning at least 2 weeks prior to radical prostatectomy.
Placebo: Given orally
Therapeutic conventional surgery: Radical prostatectomy for treatment of prostate cancer</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Circulating Prostate Cells (CPCs) in the Blood as Determined by qRT-PCR for PSA on RNA Extracted From PBMNCs</title>
        <description>Blood will be collected to analyze the number of CPC's at screening, after 1-month of treatment, at surgery and at 1 and 12 months after surgery.</description>
        <time_frame>At screening, after 1-month of treatment, at surgery and at 1 and 12 months after surgery</time_frame>
        <population>Data was not collected for analysis of this endpoint due to the study closing before the accrual goal was met.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I - Genistein</title>
            <description>Patients receive oral genistein once daily for 3 months beginning at least 1 month prior to radical prostatectomy.
Genistein: Given orally
Therapeutic conventional surgery: Radical prostatectomy for treatment of prostate cancer</description>
          </group>
          <group group_id="O2">
            <title>Arm II - Placebo</title>
            <description>Patients receive an oral placebo once daily for 3 months beginning at least 1 month prior to radical prostatectomy.
Placebo: Given orally
Therapeutic conventional surgery: Radical prostatectomy for treatment of prostate cancer</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Circulating Prostate Cells (CPCs) in the Blood as Determined by qRT-PCR for PSA on RNA Extracted From PBMNCs</title>
          <description>Blood will be collected to analyze the number of CPC's at screening, after 1-month of treatment, at surgery and at 1 and 12 months after surgery.</description>
          <population>Data was not collected for analysis of this endpoint due to the study closing before the accrual goal was met.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Natural History of Circulating Prostate Cells (CPCs) in a Cohort of Subjects Prior to and Post Radical Prostatectomy</title>
        <description>Blood will be drawn to analyze the natural history of circulating prostate cells (CPCs) in a cohort of subjects at baseline and 1 and 12 months after surgery.</description>
        <time_frame>At baseline, 1 and 12 months after surgery</time_frame>
        <population>Data was not collected for analysis of this endpoint due to the study closing before the accrual goal was met.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I - Genistein</title>
            <description>Patients receive oral genistein once daily for 3 months beginning at least 1 month prior to radical prostatectomy.
Genistein: Given orally
Therapeutic conventional surgery: Radical prostatectomy for treatment of prostate cancer</description>
          </group>
          <group group_id="O2">
            <title>Arm II - Placebo</title>
            <description>Patients receive an oral placebo once daily for 3 months beginning at least 1 month prior to radical prostatectomy.
Placebo: Given orally
Therapeutic conventional surgery: Radical prostatectomy for treatment of prostate cancer</description>
          </group>
        </group_list>
        <measure>
          <title>Natural History of Circulating Prostate Cells (CPCs) in a Cohort of Subjects Prior to and Post Radical Prostatectomy</title>
          <description>Blood will be drawn to analyze the natural history of circulating prostate cells (CPCs) in a cohort of subjects at baseline and 1 and 12 months after surgery.</description>
          <population>Data was not collected for analysis of this endpoint due to the study closing before the accrual goal was met.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measure the Effect of Genistein on Select Gene and Protein Expressions in Prostate Tissue</title>
        <description>At baseline and time of surgery, tissue will be collected to measure the effect of genistein on select gene and protein expressions in prostate tissue.</description>
        <time_frame>At baseline and at time of surgery</time_frame>
        <population>Data was not collected for analysis of this endpoint due to the study closing before the accrual goal was met.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I - Genistein</title>
            <description>Patients receive oral genistein once daily for 3 months beginning at least 1 month prior to radical prostatectomy.
Genistein: Given orally
Therapeutic conventional surgery: Radical prostatectomy for treatment of prostate cancer</description>
          </group>
          <group group_id="O2">
            <title>Arm II - Placebo</title>
            <description>Patients receive an oral placebo once daily for 3 months beginning at least 1 month prior to radical prostatectomy.
Placebo: Given orally
Therapeutic conventional surgery: Radical prostatectomy for treatment of prostate cancer</description>
          </group>
        </group_list>
        <measure>
          <title>Measure the Effect of Genistein on Select Gene and Protein Expressions in Prostate Tissue</title>
          <description>At baseline and time of surgery, tissue will be collected to measure the effect of genistein on select gene and protein expressions in prostate tissue.</description>
          <population>Data was not collected for analysis of this endpoint due to the study closing before the accrual goal was met.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measurement of PSA in Serum and Plasma by Nanotechnology</title>
        <description>Blood will be collected to measure PSA in serum and plasma by nanotechnology at screening, after 1-month of treatment, at surgery and at 1 and 12 months after surgery.</description>
        <time_frame>At screening, after 1-month of treatment, at surgery and at 1 and 12 months after surgery</time_frame>
        <population>Data was not collected for analysis of this endpoint due to the study closing before the accrual goal was met.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I - Genistein</title>
            <description>Patients receive oral genistein once daily for 3 months beginning at least 1 month prior to radical prostatectomy.
Genistein: Given orally
Therapeutic conventional surgery: Radical prostatectomy for treatment of prostate cancer</description>
          </group>
          <group group_id="O2">
            <title>Arm II - Placebo</title>
            <description>Patients receive an oral placebo once daily for 3 months beginning at least 1 month prior to radical prostatectomy.
Placebo: Given orally
Therapeutic conventional surgery: Radical prostatectomy for treatment of prostate cancer</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement of PSA in Serum and Plasma by Nanotechnology</title>
          <description>Blood will be collected to measure PSA in serum and plasma by nanotechnology at screening, after 1-month of treatment, at surgery and at 1 and 12 months after surgery.</description>
          <population>Data was not collected for analysis of this endpoint due to the study closing before the accrual goal was met.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events assessed at the following timepoints for the study: at the start of treatment, at surgery or radiation, at clinic visits occurring 1-3 months post-surgery, or post-initiation of radiation therapy, or at 3 months for those not undergoing surgery or radiation, as well as at a 4 month telephone contact.</time_frame>
      <desc>Adverse events were collected by patient reports</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm I - Genistein</title>
          <description>Patients receive oral genistein once daily for 3 months beginning at least 1 month prior to radical prostatectomy.
Genistein: Given orally
Therapeutic conventional surgery: Radical prostatectomy for treatment of prostate cancer</description>
        </group>
        <group group_id="E2">
          <title>Arm II - Placebo</title>
          <description>Patients receive an oral placebo once daily for 3 months beginning at least 1 month prior to radical prostatectomy.
Placebo: Given orally
Therapeutic conventional surgery: Radical prostatectomy for treatment of prostate cancer</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>INR Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Large pimple</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Emergency right inguinal repair</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was closed by an internal safety and data monitoring committee due to slow accrual of the study.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>William Catalona, MD</name_or_title>
      <organization>Northwestern University</organization>
      <phone>312-695-1301</phone>
      <email>WCatalona@nm.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

